Foundation Medicine Announces Strategic Collaboration with Arvinas
Initial Goal of Collaboration is to Develop FoundationOne®Liquid CDx as a Companion Diagnostic for Bavdegalutamide (ARV-110), Arvinas’ Investigational Androgen Receptor-Targeting PROTAC® Protein DegraderCAMBRIDGE, Mass.--(BUSINESS WIRE)--#ASCO22--Today Foundation Medicine, Inc., a pioneer in molecular profiling for...
Source: pharmiweb.com